Skip to main content
. 2023 Sep 22;24(19):14427. doi: 10.3390/ijms241914427

Table 3.

Summary of the trials focused on chemotherapies (CT).

Trial Number of Patients Population Prior CDK4/6is Subsequent CT Efficacy PFS (Months)
1-US study [91] 525 Progression on CDK4/6is Any Capecitabine or Taxanes (35.6%) NA NA
2-US study [92] 1210 Progression on first-line CDK4/6is

  • Palbociclib 88.2%

  • Ribociclib 7.2%

  • Abemaciclib 4.6%

 NA NA 3.71
Russian study [144] 54 Progression on CDK4/6is

  • Palbociclib 75.9%

  • Ribociclib 22.2%

  • Both 1.9%

  • Eribulin 61.1%

  • Others 38.9 %

  • PR 24.4%

  • SD 66.7%

 10.0
DESTINY-Breast04 (HR+ cohort) [145] 494 Progression on CT or OT Any (about 70% of pts) T-DXd vs. TPC (eribulin, capecitabine, nab-paclitaxel, gemcitabine or paclitaxel) 52.3% T-DXd vs. 16.3% TPC 10.1 T-DXd vs. 5.4 TPC
TROPiCS-02 [148] 543 Progression after CDK4/6is and at least 2 chemotherapeutic agents (including a taxane) Any (98% of pts) SG vs. TPC (eribulin, capecitabine, gemcitabine or vinorelbine) 21% SG vs. 14% TPC 5.5 SG vs. 4.0 TPC

Abbreviation: CT = chemotherapy; OT = ormonal therapy; PR = partial response; SD = stable disease; PFS = progression-free survival; TPC = Treatment of Physician’s Choice; T-DXd = trastuzumab deruxtecan; SG = sacituzumab govitecan.